TNF and infection: Other evidence of a trend towards pharmacologic activity include (i) the significantly lower level of TNFα in celgosivir-treated patients compared to placebo controls during the early stage of treatment, independent of prior infection status and (ii) enhanced NS1 clearance in secondary infection following celgosivir treatment [17].